How to Get Alprostadil (Caverject/MUSE) in Nevada

What Is Alprostadil and Why Is It Prescribed?

Alprostadil is synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle in the corpus cavernosum, increasing arterial inflow and producing an erection independent of the nitric-oxide pathway used by PDE5 inhibitors. It is FDA-approved for erectile dysfunction and is the most widely studied intracavernosal vasoactive agent in urology. [1]

In the landmark Linet et al. trial published in the New England Journal of Medicine (N=683), alprostadil intracavernosal injection produced satisfactory erections in 94% of injection attempts versus 11% with placebo (P<0.001). [2] That response rate explains why urologists consider it a first-line option when sildenafil, tadalafil, or vardenafil fail or are contraindicated. [3]

Alprostadil reaches patients in two FDA-approved delivery systems. Caverject (Pfizer) and its authorized generic are injected directly into the corpus cavernosum using a fine-gauge needle. MUSE (Medicated Urethral System for Erection) is a small pellet inserted into the urethral meatus with a single-use applicator. Each route has distinct dosing ranges, titration schedules, and side-effect profiles, so the prescribing clinician's choice depends on patient dexterity, prior surgical history, and personal preference. [4]

The American Urological Association (AUA) 2018 guideline on erectile dysfunction states: "Intracavernosal injection therapy is appropriate for men who fail or do not tolerate oral pharmacotherapy." [5] That recommendation covers both brand and compounded formulations.

Nevada Telehealth Rules for Alprostadil Prescribing

Nevada permits telehealth prescribing of alprostadil without a mandatory prior in-person exam, provided the clinician establishes a valid patient-provider relationship through a synchronous audio-video visit. [6]

Nevada Revised Statutes (NRS) 629.515 defines telehealth broadly and requires only that the standard of care achievable in person is met during the remote encounter. The Nevada State Board of Medical Examiners and the Nevada State Board of Osteopathic Medicine have both issued guidance confirming that Schedule-unscheduled prescription medications, including PGE1 agents, may be prescribed via telemedicine when clinical judgment supports it. Because alprostadil is not a controlled substance under the DEA or Nevada law, it does not require the additional prescribing safeguards that apply to testosterone or opioids. [7]

A typical telehealth workflow for alprostadil in Nevada runs as follows. The patient completes an intake form covering medical history, current medications, and prior erectile dysfunction treatments. The clinician reviews the form, conducts a video visit (usually 15 to 20 minutes), and, if appropriate, sends a prescription to a local retail pharmacy or a mail-order 503A compounding pharmacy. Labs are reviewed asynchronously or ordered through a partnered draw site. The prescription arrives at most Nevada retail chains within 24 hours, and compounded alprostadil typically ships within two to three business days. [8]

HealthRX-affiliated clinicians operating in Nevada follow a standardized intake that screens for sickle cell anemia, leukemia, penile anatomical abnormalities (including Peyronie's disease greater than 30-degree curvature), and concurrent anticoagulant use. Each of these conditions warrants additional caution before initiating intracavernosal therapy. [9]

Which Clinicians Can Prescribe Alprostadil in Nevada?

Any licensed Nevada prescriber with authority to write non-controlled prescriptions may prescribe alprostadil. That includes MDs and DOs licensed under NRS Chapter 630 and 633, nurse practitioners (NPs) with prescriptive authority under NRS 632, and physician assistants (PAs) under NRS 630. [10]

Nevada NPs have full practice authority as of 2013, meaning they may prescribe without physician supervision after completing 2 to 000 hours of supervised practice. A PA must practice under a physician collaboration agreement, but the agreement does not restrict the medication list beyond controlled substances requiring a co-signature. [11] In practical terms, a patient seeing a telehealth NP in Nevada faces no additional prescribing barrier compared to seeing an MD.

Urologists who perform in-office penile injection training retain a clinical advantage for first-time users: they can titrate the dose in a monitored setting and manage priapism on site if the erection exceeds four hours. For patients using telehealth-only, the prescriber should counsel on the 4-hour rule (seek emergency care for any erection lasting beyond four hours) and provide a written instruction sheet. [12]

What Labs Are Required Before Starting Alprostadil in Nevada?

No universal lab panel is required by FDA labeling before starting alprostadil, but clinical guidelines and HealthRX's internal protocol recommend evaluating factors that could amplify vascular risk or alter dosing decisions. [13]

The HealthRX Pre-Alprostadil Lab Framework for telehealth initiation in Nevada includes five targeted tests:

1. Fasting glucose and HbA1c. Diabetes is present in roughly 50% of men with erectile dysfunction. [14] Uncontrolled hyperglycemia (HbA1c above 9%) may predict a higher required dose and a shorter duration of effect.

2. Total and free testosterone. Hypogonadism affects 30 to 40% of men with ED. [15] If total testosterone is below 300 ng/dL on two morning draws, treating the underlying hypogonadism first or concurrently may improve response to alprostadil.

3. Lipid panel. Dyslipidemia is an independent risk factor for vascular ED. [16] The result does not gate alprostadil access but informs cardiovascular risk counseling.

4. CBC with differential. Screens for sickle cell disease or trait, polycythemia vera, and other hematologic conditions that increase priapism risk.

5. PSA (age 40 and older). Not required for alprostadil, but HealthRX uses the telehealth visit as an opportunity for prostate health screening aligned with AUA early detection guidelines. [17]

Nevada LabCorp and Quest Diagnostics locations accept electronic lab orders generated during a telehealth visit. Results typically return within one to two business days for standard panels.

How to Access Alprostadil Through a Nevada Pharmacy

Alprostadil is available through three pathways in Nevada: brand retail, generic retail, and 503A compounding.

Brand and generic retail. Caverject Impulse (Pfizer, 10 mcg and 20 mcg dual-chamber syringe) is stocked at major Nevada chains including Walgreens, CVS, and Smith's. Without insurance, brand-name Caverject carries a retail price between $90 and $160 per single-use kit depending on dose. Generic alprostadil for injection is available from several manufacturers and typically prices 30 to 50% lower. MUSE suppositories (125 mcg, 250 mcg, 500 mcg, 1 to 000 mcg) are less consistently stocked but can be special-ordered within 24 to 48 hours at most retail locations. [18]

503A compounding pharmacies. A 503A pharmacy compounds medications for individual patients under a valid prescription. Nevada-licensed 503A compounding pharmacies may legally prepare alprostadil for intracavernosal injection in customized concentrations (for example, 10 mcg/0.1 mL, 20 mcg/0.1 mL, or in combination formulations such as trimix, which pairs alprostadil with phentolamine and papaverine). [19] Compounded alprostadil is not FDA-approved, but it is legal under state pharmacy law and USP Chapter 797 sterile compounding standards. Shipping is permitted within Nevada and across state lines when the receiving state allows it.

Insurance and prior authorization. Nevada Medicaid excludes alprostadil for erectile dysfunction. Private insurers vary widely. When prior authorization is required, the treating clinician typically must document: (a) a confirmed diagnosis of erectile dysfunction by ICD-10 code N52.xx, (b) a trial of at least one oral PDE5 inhibitor at an adequate dose and duration with inadequate response or documented contraindication, and (c) absence of contraindications to alprostadil. Some plans require a urology specialist note. Obtaining all documentation before submission reduces average prior authorization time from 10 to 14 days to 5 to 7 days. [20]

Dosing and Administration Basics

For Caverject, the FDA-approved starting dose is 2.5 mcg for neurogenic erectile dysfunction and 2.5 mcg for vasculogenic or mixed ED. The dose is titrated upward in 2.5 to 5 mcg increments under medical supervision until an erection suitable for intercourse is achieved or side effects limit further titration. The maximum recommended single dose is 60 mcg, and the injection should not be used more than once in 24 hours or more than three times per week. [21]

For MUSE, the starting dose is 125 to 250 mcg. Titration proceeds to 500 mcg, then 1 to 000 mcg based on response. The patient should urinate before inserting the suppository, as urethral moisture improves pellet dissolution. Standing or walking for 10 minutes after insertion increases systemic absorption. [22]

Side effects differ between routes. Penile pain after injection is reported by 10 to 44% of users in clinical trials; it is generally mild and decreases with continued use. [2] Urethral burning after MUSE is reported by up to 36% of users. Hypotension from systemic absorption occurs in roughly 3% of MUSE users and is more common in men also taking antihypertensives. [23] Priapism (erection lasting longer than four hours) occurs in fewer than 1% of properly dosed cases but requires immediate urologic intervention. [24]

Transferring an Existing Alprostadil Prescription to Nevada

A patient relocating to Nevada, or spending extended time in the state, may transfer an existing retail pharmacy prescription for alprostadil following standard Nevada pharmacy transfer rules. Nevada law (NAC 639.700) allows the originating pharmacy to transfer a non-controlled prescription once. The receiving Nevada pharmacy may then refill the prescription up to the authorized refills remaining on the original order. [25]

For compounded alprostadil from a 503A pharmacy outside Nevada, the prescription must be rewritten by a Nevada-licensed prescriber, since compounded preparations are patient-specific and tied to the issuing clinician's license jurisdiction. A telehealth visit with a Nevada-licensed provider resolves this within 24 to 48 hours in most cases. [26]

Patients traveling temporarily (fewer than 30 days) may carry a sufficient supply of alprostadil purchased in their home state. Nevada has no law restricting possession of prescription medication obtained lawfully in another state, provided the quantity is consistent with personal use. [27]

Managing Prior Authorization in Nevada

Prior authorization (PA) for alprostadil is required by most Nevada commercial plans and by Medicare Part D when the plan's formulary places alprostadil at a tier requiring step therapy. The documentation package that minimizes denial rates includes seven elements. [28]

First, a clinical note documenting the diagnosis, onset, and severity of erectile dysfunction scored on a validated instrument such as the International Index of Erectile Function (IIEF-5). Second, evidence of an adequate trial of at least one PDE5 inhibitor (typically sildenafil 50 to 100 mg or tadalafil 10 to 20 mg for at least four separate attempts). Third, the reason for PDE5 inhibitor failure or contraindication. Fourth, the prescribing clinician's NPI and Nevada license number. Fifth, the requested drug name, dose, and quantity. Sixth, the relevant ICD-10 diagnosis code (N52.01, N52.9 depending on etiology). Seventh, supporting lab results if the plan requires documentation of underlying comorbidities such as diabetes or hypogonadism. [29]

Nevada law (NRS 695G.200) requires commercial health insurers to resolve standard prior authorization requests within three business days and urgent requests within one business day. If a PA is denied, the patient has the right to an internal appeal and an external independent review. The Nevada Division of Insurance maintains a consumer assistance line at 1-800-992-0900 for patients facing insurer non-compliance. [30]

Safety Monitoring During Long-Term Alprostadil Use

Patients using alprostadil for more than six months should receive at least one annual follow-up visit, in person or via telehealth, to assess for fibrosis of the corpus cavernosum. Chronic intracavernosal injections carry a 4 to 12% incidence of penile fibrosis or nodule formation over 12 to 18 months of regular use. [31] Clinicians examine or ask patients about any palpable changes along the shaft before renewing prescriptions.

Blood pressure should be reassessed in patients using MUSE who are also on three or more antihypertensive agents, given the synergistic vasodilatory effect. The prescribing clinician should also confirm that no new contraindications have emerged, including initiation of alpha-blocker therapy for benign prostatic hyperplasia, which potentiates alprostadil-associated hypotension. [32]

A 2020 systematic review in Journal of Sexual Medicine (N=3,247 pooled patients across 22 trials) found that dropout from intracavernosal alprostadil therapy at 12 months reached 40 to 60%, with the primary reasons being pain (28%), loss of spontaneity (22%), and partner preference for oral therapy (18%). [33] Shared decision-making that addresses these expectations before initiating therapy improves 12-month adherence.

Combination and Alternative Injectable Therapies Available in Nevada

When alprostadil monotherapy produces insufficient response or dose-limiting pain, Nevada prescribers may consider trimix (alprostadil plus phentolamine plus papaverine) or bimix (papaverine plus phentolamine) compounded by a 503A pharmacy. [34] Trimix is not FDA-approved as a fixed combination, but its components are individually approved vasoactive agents, and its compounded use is supported by clinical literature and AUA guidance. [35]

A 1995 study in Urology (N=116) found that trimix produced satisfactory erections in 87% of men who had inadequate response to alprostadil monotherapy at maximum tolerable doses. [36] The lower alprostadil concentration in trimix (typically 2 to 10 mcg/mL compared to 10 to 40 mcg/mL in alprostadil monotherapy) reduces penile pain while maintaining efficacy through synergistic vasodilation.

Nevada 503A pharmacies offering trimix compounds include providers that ship directly to patients after receiving a valid Nevada clinician prescription. Turnaround from prescription receipt to patient delivery is typically two to four business days when shipped refrigerated overnight. Trimix must be stored at 2, 8 degrees Celsius and used within 30 days of compounding. [37]